Effects of Hormones

  • Tricia A. Murdock
  • Emanuela F. T. Veras
  • Robert J. Kurman
  • Michael T. Mazur


Women receive hormone preparations for a variety of reasons, including birth control and treatment for abnormal uterine bleeding, perimenopausal and postmenopausal symptoms, endometriosis, endometrial hyperplasia, endometrioid carcinoma, breast carcinoma, and certain types of infertility. Usually the exogenous hormone is some form of progestin, but estrogenic and even androgenic hormones are used for some disorders. Since the endometrium has estrogen and progesterone receptors, it shows the effects of these hormones.


Hormones Estrogenic hormones Progestin therapy Oral contraceptives Postmenopausal hormone replacement Abnormal uterine bleeding Infertility therapy Tamoxifen 


  1. 1.
    Fritz MA, Speroff L. Clinical gynecologic endocrinology and infertility. 8th ed. Philadelphia: Lippincott Williams & Wilkins; 2010.Google Scholar
  2. 2.
    Maclennan AH, Broadbent JL, Lester S, Moore V. Oral oestrogen and combined oestrogen/progestogen therapy versus placebo for hot flushes. Cochrane Database Syst Rev. 2004;18:CD002978.Google Scholar
  3. 3.
    Greendale GA, Reboussin BA, Hogan P, Barnabei VM, Shumaker S, Johnson S, Barrett-Connor E. Symptom relief and side effects of postmenopausal hormones: results from the Postmenopausal Estrogen/Progestin Interventions Trial. Obstet Gynecol. 1998;92:982–8.PubMedGoogle Scholar
  4. 4.
    Cintron D, Lahr BD, Bailey KR, Santoro N, Lloyd R, Manson JE, Neal-Perry G, Pal L, Taylor HS, Wharton W, Naftolin F, Harman SM, Miller VM. Effects of oral versus transdermal menopausal hormone treatments on self-reported sleep domains and their association with vasomotor symptoms in recently menopausal women enrolled in the Kronos Early Estrogen Prevention Study (KEEPS). Menopause. 2018;25:145–53.PubMedPubMedCentralGoogle Scholar
  5. 5.
    Faubion SS, Sood R, Kapoor E. Genitourinary syndrome of menopause: management strategies for the clinician. Mayo Clin Proc. 2017;92:1842–9.PubMedGoogle Scholar
  6. 6.
    Gandhi J, Chen A, Dagur G, Suh Y, Smith N, Cali B, Khan SA. Genitourinary syndrome of menopause: an overview of clinical manifestations, pathophysiology, etiology, evaluation, and management. Am J Obstet Gynecol. 2016;215:704–11.PubMedGoogle Scholar
  7. 7.
    Gartlehner G, Patel SV, Feltner C, Weber RP, Long R, Mullican K, Boland E, Lux L, Viswanathan M. Hormone therapy for the primary prevention of chronic conditions in postmenopausal women: evidence report and systematic review for the US Preventive Services Task Force. JAMA. 2017;318:2234–49.PubMedGoogle Scholar
  8. 8.
    Schiff I. Menopause. In: Kistner RW, editor. Gynecology: principles and practice. 7th ed. Chicago: Year Book Medical Pub; 1999.Google Scholar
  9. 9.
    Effects of hormone replacement therapy on endometrial histology in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. The Writing Group for the PEPI Trial. JAMA. 1996;275:370–75.Google Scholar
  10. 10.
    Ferenczy A, Gelfand MM. Endometrial histology and bleeding patterns in post-menopausal women taking sequential, combined estradiol and dydrogesterone. Maturitas. 1997;26:219–26.PubMedGoogle Scholar
  11. 11.
    Gomes AM, Baracat EC, Simões MJ, Haidar MA, Focchi GR, Evêncio-Neto J, de Lima GR. Morphologic and morphometric aspects of the endometrium of postmenopausal women before and after cyclic oestrogen replacement treatment. Eur J Obstet Gynecol Reprod Biol. 1997;74:79–82.PubMedGoogle Scholar
  12. 12.
    Deligdisch L. Hormonal pathology of the endometrium. Mod Pathol. 2000;13:285–94.PubMedGoogle Scholar
  13. 13.
    Grady D, Rubin SM, Petitti DB, Fox CS, Black D, Ettinger B, Ernster VL, Cummings SR. Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med. 1992;117:1016–37.PubMedGoogle Scholar
  14. 14.
    Whitehead MI, Fraser D. The effects of estrogens and progestogens on the endometrium. Modern approach to treatment. Obstet Gynecol Clin N Am. 1987;14:299–320.Google Scholar
  15. 15.
    Furness S, Roberts H, Marjoribanks J, Lethaby A. Hormone therapy in postmenopausal women and risk of endometrial hyperplasia. Cochrane Database Syst Rev. 2012;8:CD000402.Google Scholar
  16. 16.
    Grady D, Gebretsadik T, Kerlikowske K, Ernster V, Petitti D. Hormone replacement therapy and endometrial cancer risk: a meta-analysis. Obstet Gynecol. 1995;85:304–13.PubMedGoogle Scholar
  17. 17.
    Sjögren LL, Mørch LS, Løkkegaard E. Hormone replacement therapy and the risk of endometrial cancer: a systematic review. Maturitas. 2016;91:25–35.PubMedGoogle Scholar
  18. 18.
    Steinauer J, Autry AM. Extended cycle combined hormonal contraception. Obstet Gynecol Clin N Am. 2007;34:43–55, viii.PubMedGoogle Scholar
  19. 19.
    Allais G, Chiarle G, Sinigaglia S, Benedetto C. Menstrual migraine: a review of current and developing pharmacotherapies for women. Expert Opin Pharmacother. 2018;19:123–36.PubMedGoogle Scholar
  20. 20.
    van Zuuren EJ, Fedorowicz Z, Carter B, Pandis N. Interventions for hirsutism (excluding laser and photoepilation therapy alone). Cochrane Database Syst Rev. 2015;4:CD010334.Google Scholar
  21. 21.
    Arowojolu AO, Gallo MF, Lopez LM, Grimes DA. Combined oral contraceptive pills for treatment of acne. Cochrane Database Syst Rev. 2012;6:CD004425.Google Scholar
  22. 22.
    Iversen L, Sivasubramaniam S, Lee AJ, Fielding S, Hannaford PC: Lifetime cancer risk and combined oral contraceptives: the Royal College of General Practitioners’ Oral Contraception Study. Am J Obstet Gynecol. 2017;216:580.e1–9.PubMedGoogle Scholar
  23. 23.
    Chiaffarino F, Parazzini F, La Vecchia C, Marsico S, Surace M, Ricci E. Use of oral contraceptives and uterine fibroids: results from a case-control study. Br J Obstet Gynaecol. 1999;106:857–60.PubMedGoogle Scholar
  24. 24.
    Ober WB. Effects of oral and intrauterine administration of contraceptives on the uterus. Hum Pathol. 1977;8:513–27.PubMedGoogle Scholar
  25. 25.
    Dallenbach-Hellweg G. Histopathology of the endometrium. 4th ed. New York: Springer; 1987.Google Scholar
  26. 26.
    Deligdisch L. Effects of hormone therapy on the endometrium. Mod Pathol. 1993;6:94–106.PubMedGoogle Scholar
  27. 27.
    Raymond EG, Lovely LP, Chen-Mok M, Seppälä M, Kurman RJ, Lessey BA. Effect of the Yuzpe regimen of emergency contraception on markers of endometrial receptivity. Hum Reprod. 2000;15:2351–5.PubMedGoogle Scholar
  28. 28.
    Swahn ML, Westlund P, Johannisson E, Bygdeman M. Effect of post-coital contraceptive methods on the endometrium and the menstrual cycle. Acta Obstet Gynecol Scand. 1996;75:738–44.PubMedGoogle Scholar
  29. 29.
    Marions L, Hultenby K, Lindell I, Sun X, Ståbi B, Gemzell Danielsson K. Emergency contraception with mifepristone and levonorgestrel: mechanism of action. Obstet Gynecol. 2002;100:65–71.PubMedGoogle Scholar
  30. 30.
    Vargas MF, Tapia-Pizarro AA, Henríquez SP, Quezada M, Salvatierra AM, Noe G, Munroe DJ, Velasquez LA, Croxatto HB. Effect of single post-ovulatory administration of levonorgestrel on gene expression profile during the receptive period of the human endometrium. J Mol Endocrinol. 2012;48:25–36.PubMedGoogle Scholar
  31. 31.
    Gemzell-Danielsson K, Berger C. P G L L: emergency contraception – mechanisms of action. Contraception. 2013;87:300–8.PubMedGoogle Scholar
  32. 32.
    Mentrikoski MJ, Shah AA, Hanley KZ, Atkins KA. Assessing endometrial hyperplasia and carcinoma treated with progestin therapy. Am J Clin Pathol. 2012;138:524–34.PubMedGoogle Scholar
  33. 33.
    Miranda MC, Mazur MT. Endometrial squamous metaplasia. An unusual response to progestin therapy of hyperplasia. Arch Pathol Lab Med. 1995;119:458–60.PubMedGoogle Scholar
  34. 34.
    Dockerty MB, Smith RA, Symmonds RE. Pseudomalignant endometrial changes induced by administration of new synthetic progestins. Proc Staff Meet Mayo Clin. 1959;34:321–8.PubMedGoogle Scholar
  35. 35.
    Cruz-Aquino M, Shenker L, Blaustein A. Pseudosarcoma of the endometrium. Obstet Gynecol. 1967;29:93–6.PubMedGoogle Scholar
  36. 36.
    Clement PB, Scully RE. Idiopathic postmenopausal decidual reaction of the endometrium. A clinicopathologic analysis of four cases. Int J Gynecol Pathol. 1988;7:152–61.PubMedGoogle Scholar
  37. 37.
    Iezzoni JC, Mills SE. Nonneoplastic endometrial signet-ring cells. Vacuolated decidual cells and stromal histiocytes mimicking adenocarcinoma. Am J Clin Pathol. 2001;115:249–55.PubMedGoogle Scholar
  38. 38.
    Critchley HO, Wang H, Jones RL, Kelly RW, Drudy TA, Gebbie AE, Buckley CH, McNeilly AS, Glasier AF. Morphological and functional features of endometrial decidualization following long-term intrauterine levonorgestrel delivery. Hum Reprod. 1998;13:1218–24.PubMedGoogle Scholar
  39. 39.
    Bernardini L, Araujo FE, Balmaceda JP. A case of permanent endometrial hypotrophy after long-term use of oral contraceptives. Hum Reprod. 1993;8:543–6.PubMedGoogle Scholar
  40. 40.
    Taylor HS, Ohleth K. Using bazedoxifene plus conjugated estrogens for treating postmenopausal women: a comprehensive review. Menopause. 2012;19:479–85.PubMedGoogle Scholar
  41. 41.
    The NAMS. Hormone therapy position statement advisory panel: the 2017 hormone therapy position statement of The North American Menopause Society. Menopause. 2017;2017(24):728–53.Google Scholar
  42. 42.
    Lello S, Capozzi A, Scambia G. The tissue-selective estrogen complex (bazedoxifene/conjugated estrogens) for the treatment of menopause. Int J Endocrinol. 2017;2017:5064725.PubMedPubMedCentralGoogle Scholar
  43. 43.
    Gelfand MM, Ferenczy A. A prospective 1-year study of estrogen and progestin in postmenopausal women: effects on the endometrium. Obstet Gynecol. 1989;74:398–402.PubMedGoogle Scholar
  44. 44.
    Ryntz T, Lobo RA. Abnormal uterine bleeding. In: Lobo RA, Gershenson DM, Lentz GM, Valea FA, editors. Comprehensive gynecology. 7th ed. Philadelphia: Elsevier; 2017. p. 621–33.Google Scholar
  45. 45.
    Feeley KM, Wells M. Hormone replacement therapy and the endometrium. J Clin Pathol. 2001;54:435–40.PubMedPubMedCentralGoogle Scholar
  46. 46.
    Byrjalsen I, Thormann L, Meinecke B, Riis BJ, Christiansen C. Sequential estrogen and progestogen therapy: assessment of progestational effects on the postmenopausal endometrium. Obstet Gynecol. 1992;79:523–8.PubMedGoogle Scholar
  47. 47.
    Carranza-Lira S, Martínez-Chéquer JC, Santa Rita MT, Ortiz de la Peña A, Pérez Y, Fernández RL. Endometrial changes according to hormone replacement therapy schedule. Menopause. 1998;5:86–9.PubMedGoogle Scholar
  48. 48.
    Habiba MA, Bell SC, Al-Azzawi F. Endometrial responses to hormone replacement therapy: histological features compared with those of late luteal phase endometrium. Hum Reprod. 1998;13:1674–82.PubMedGoogle Scholar
  49. 49.
    Magos AL, Brincat M, Studd JW, Wardle P, Schlesinger P, O’Dowd T. Amenorrhea and endometrial atrophy with continuous oral estrogen and progestogen therapy in postmenopausal women. Obstet Gynecol. 1985;65:496–9.PubMedGoogle Scholar
  50. 50.
    Hillard TC, Siddle NC, Whitehead MI, Fraser DI, Pryse-Davies J. Continuous combined conjugated equine estrogen-progestogen therapy: effects of medroxyprogesterone acetate and norethindrone acetate on bleeding patterns and endometrial histologic diagnosis. Am J Obstet Gynecol. 1992;167:1–7.PubMedGoogle Scholar
  51. 51.
    Piegsa K, Calder A, Davis JA, McKay-Hart D, Wells M, Bryden F. Endometrial status in post-menopausal women on long-term continuous combined hormone replacement therapy (Kliofem). A comparative study of endometrial biopsy, outpatient hysteroscopy and transvaginal ultrasound. Eur J Obstet Gynecol Reprod Biol. 1997;72:175–80.PubMedGoogle Scholar
  52. 52.
    Sturdee DW. Endometrial morphology and bleeding patterns as a function of progestogen supplementation. Int J Fertil Menopausal Stud. 1996;41:22–8.PubMedGoogle Scholar
  53. 53.
    Udoff L, Langenberg P, Adashi EY. Combined continuous hormone replacement therapy: a critical review. Obstet Gynecol. 1995;86:306–16.PubMedGoogle Scholar
  54. 54.
    Fernández-Murga L, Hermenegildo C, Tarín JJ, García-Pérez M-Á, Cano A. Endometrial response to concurrent treatment with vaginal progesterone and transdermal estradiol. Climacteric. 2012;15:455–9.PubMedGoogle Scholar
  55. 55.
    Moyer DL, de Lignieres B, Driguez P, Pez JP. Prevention of endometrial hyperplasia by progesterone during long-term estradiol replacement: influence of bleeding pattern and secretory changes. Fertil Steril. 1993;59:992–7.PubMedGoogle Scholar
  56. 56.
    Bjarnason K, Cerin A, Lindgren R, Weber T. Adverse endometrial effects during long cycle hormone replacement therapy. Scandinavian Long Cycle Study Group. Maturitas. 1999;32:161–70.PubMedGoogle Scholar
  57. 57.
    Sturdee DW, Ulrich LG, Barlow DH, Wells M, Campbell MJ, Vessey MP, Nielsen B, Anderson MC, Bragg AJ. The endometrial response to sequential and continuous combined oestrogen-progestogen replacement therapy. BJOG. 2000;107:1392–400.PubMedGoogle Scholar
  58. 58.
    Elliott J, Connor ME, Lashen H. The value of outpatient hysteroscopy in diagnosing endometrial pathology in postmenopausal women with and without hormone replacement therapy. Acta Obstet Gynecol Scand. 2003;82:1112–9.PubMedGoogle Scholar
  59. 59.
    Omodei U, Ferrazzi E, Ramazzotto F, Becorpi A, Grimaldi E, Scarselli G, Spagnolo D, Spagnolo L, Torri W. Endometrial evaluation with transvaginal ultrasound during hormone therapy: a prospective multicenter study. Fertil Steril. 2004;81:1632–7.PubMedGoogle Scholar
  60. 60.
    Heikkinen J, Vaheri R, Kainulainen P, Timonen U. Long-term continuous combined hormone replacement therapy in the prevention of postmenopausal bone loss: a comparison of high- and low-dose estrogen-progestin regimens. Osteoporos Int. 2000;11:929–37.PubMedGoogle Scholar
  61. 61.
    Nand SL, Webster MA, Baber R, O’Connor V. Bleeding pattern and endometrial changes during continuous combined hormone replacement therapy. The Ogen/Provera Study Group. Obstet Gynecol. 1998;91:678–84.PubMedGoogle Scholar
  62. 62.
    Oosterbaan HP, van Buuren AH, Schram JH, van Kempen PJ, Ubachs JM, van Leusden HA, Beyer GP. The effects of continuous combined transdermal oestrogen-progestogen treatment on bleeding patterns and the endometrium in postmenopausal women. Maturitas. 1995;21:211–9.PubMedGoogle Scholar
  63. 63.
    Varila E, Wahlström T, Rauramo I. A 5-year follow-up study on the use of a levonorgestrel intrauterine system in women receiving hormone replacement therapy. Fertil Steril. 2001;76:969–73.PubMedGoogle Scholar
  64. 64.
    Kurman RJ, Félix JC, Archer DF, Nanavati N, Arce J, Moyer DL. Norethindrone acetate and estradiol-induced endometrial hyperplasia. Obstet Gynecol. 2000;96:373–9.PubMedGoogle Scholar
  65. 65.
    Te Linde RW, Henriksen E. Decidua like changes in the endometrium without pregnancy. Am J Obstet Gynecol. 1940;39:733–49.Google Scholar
  66. 66.
    Dallenbach-Hellweg G, Hohagen F. On the problem of premature decidualization induced by the embryo transfer. Lab Investig. 1985;52:17A.Google Scholar
  67. 67.
    Tamada T, Okagaki T, Maruyama M, Matsumoto S. Endometrial histology associated with an intrauterine contraceptive device. Am J Obstet Gynecol. 1967;98:811–7.PubMedGoogle Scholar
  68. 68.
    Bonney WA, Glasser SR, Clewe TH, Noyes RW, Cooper CL. Endometrial response to the intrauterine device. Am J Obstet Gynecol. 1966;96:101–13.PubMedGoogle Scholar
  69. 69.
    Mutter GL, Bergeron C, Deligdisch L, Ferenczy A, Glant M, Merino M, Williams ARW, Blithe DL. The spectrum of endometrial pathology induced by progesterone receptor modulators. Mod Pathol. 2008;21:591–8.PubMedGoogle Scholar
  70. 70.
    Williams ARW, Bergeron C, Barlow DH, Ferenczy A. Endometrial morphology after treatment of uterine fibroids with the selective progesterone receptor modulator, ulipristal acetate. Int J Gynecol Pathol. 2012;31:556–69.PubMedGoogle Scholar
  71. 71.
    Nogales FF, Crespo-Lora V, Cruz-Viruel N, Chamorro-Santos C, Bergeron C. Endometrial changes in surgical specimens of perimenopausal patients treated with ulipristal acetate for uterine leiomyomas. Int J Gynecol Pathol. 2017 Sep 13. doi: 10.1097/PGP.0000000000000450. [Epub ahead of print].Google Scholar
  72. 72.
    Donnez J, Donnez O, Matule D, Ahrendt H-J, Hudecek R, Zatik J, Kasilovskiene Z, Dumitrascu MC, Fernandez H, Barlow DH, Bouchard P, Fauser BCJM, Bestel E, Loumaye E. Long-term medical management of uterine fibroids with ulipristal acetate. Fertil Steril. 2016;105:165–73.e4.PubMedGoogle Scholar
  73. 73.
    Vosse M, Renard F, Coibion M, Neven P, Nogaret JM, Hertens D. Endometrial disorders in 406 breast cancer patients on tamoxifen: the case for less intensive monitoring. Eur J Obstet Gynecol Reprod Biol. 2002;101:58–63.PubMedGoogle Scholar
  74. 74.
    Goldstein SR. The effect of SERMs on the endometrium. Ann N Y Acad Sci. 2001;949:237–42.PubMedGoogle Scholar
  75. 75.
    Cohen I, Altaras MM, Shapira J, Tepper R, Rosen DJ, Cordoba M, Zalel Y, Figer A, Yigael D, Beyth Y. Time-dependent effect of tamoxifen therapy on endometrial pathology in asymptomatic postmenopausal breast cancer patients. Int J Gynecol Pathol. 1996;15:152–7.PubMedGoogle Scholar
  76. 76.
    Leslie KK, Walter SA, Torkko K, Stephens JK, Thompson C, Singh M. Effect of tamoxifen on endometrial histology, hormone receptors, and cervical cytology: a prospective study with follow-up. Appl Immunohistochem Mol Morphol. 2007;15:284–93.PubMedGoogle Scholar
  77. 77.
    López DML, Fernández YG, Sánchez AV, Alvarez MI, Reynaldo MIL, Delgado RC. Baseline hysteroscopic assessment of endometrium in asymptomatic postmenopausal women with estrogen receptor-positive breast cancer. Menopause. 2013;20:64–71.PubMedGoogle Scholar
  78. 78.
    Lubián López DM, Orihuela López F, García-Berbel Molina L, Boza Novo P, Pozuelo Solís E, Menor Almagro D, Comino Delgado R. Endometrial polyps in obese asymptomatic pre and postmenopausal patients with breast cancer: is screening necessary? Gynecol Oncol. 2014;133:56–62.PubMedGoogle Scholar
  79. 79.
    Bissett D, Davis JA, George WD. Gynaecological monitoring during tamoxifen therapy. Lancet. 1994;344:1244.PubMedGoogle Scholar
  80. 80.
    Committee Opinion No. 601. Tamoxifen and uterine cancer. Obstet Gynecol. 2014;123:1394–7.Google Scholar
  81. 81.
    Bertelli G, Valenzano M, Costantini S, Rissone R, Angiolini C, Signorini A, Gustavino C. Limited value of sonohysterography for endometrial screening in asymptomatic, postmenopausal patients treated with tamoxifen. Gynecol Oncol. 2000;78:275–7.PubMedGoogle Scholar
  82. 82.
    Cohen I, Perel E, Flex D, Tepper R, Altaras MM, Cordoba M, Beyth Y. Endometrial pathology in postmenopausal tamoxifen treatment: comparison between gynaecologically symptomatic and asymptomatic breast cancer patients. J Clin Pathol. 1999;52:278–82.PubMedPubMedCentralGoogle Scholar
  83. 83.
    Marchesoni D, Driul L, Fabiani G, Di Loreto C, Cataldi P, Mozzanega B. Endometrial histologic changes in post-menopausal breast cancer patients using tamoxifen. Int J Gynaecol Obstet. 2001;75:257–62.PubMedGoogle Scholar
  84. 84.
    Seoud M, Shamseddine A, Khalil A, Salem Z, Saghir N, Bikhazi K, Bitar N, Azar G, Kaspar H. Tamoxifen and endometrial pathologies: a prospective study. Gynecol Oncol. 1999;75:15–9.PubMedGoogle Scholar
  85. 85.
    Ozşener S, Ozaran A, Itil I, Dikmen Y. Endometrial pathology of 104 postmenopausal breast cancer patients treated with tamoxifen. Eur J Gynaecol Oncol. 1998;19:580–3.PubMedGoogle Scholar
  86. 86.
    LE Donne M, Alibrandi A, Ciancimino L, Azzerboni A, Chiofalo B, Triolo O. Endometrial pathology in breast cancer patients: effect of different treatments on ultrasonographic, hysteroscopic and histological findings. Oncol Lett. 2013;5:1305–10.Google Scholar
  87. 87.
    Cohen I, Figer A, Altaras MM, Tepper R, Shapira J, Cordoba M, Yigael D, Arbel Y, Beyth Y. Common endometrial decidual reaction in postmenopausal breast cancer patients treated with tamoxifen and progestogens. Int J Gynecol Pathol. 1996;15:17–22.PubMedGoogle Scholar
  88. 88.
    Cohen I, Shapira J, Altaras M, Cordoba M, Rosen D, Beyth Y. Endometrial decidual changes in a postmenopausal woman treated with tamoxifen and megestrol acetate. Br J Obstet Gynaecol. 1992;99:773–4.PubMedGoogle Scholar
  89. 89.
    Andersson M, Storm HH, Mouridsen HT. Incidence of new primary cancers after adjuvant tamoxifen therapy and radiotherapy for early breast cancer. J Natl Cancer Inst. 1991;83:1013–7.PubMedGoogle Scholar
  90. 90.
    Segna RA, Dottino PR, Deligdisch L, Cohen CJ. Tamoxifen and endometrial cancer. Mt Sinai J Med. 1992;59:416–8.PubMedGoogle Scholar
  91. 91.
    Magriples U, Naftolin F, Schwartz PE, Carcangiu ML. High-grade endometrial carcinoma in tamoxifen-treated breast cancer patients. J Clin Oncol. 1993;11:485–90.PubMedGoogle Scholar
  92. 92.
    Gusberg SB. Tamoxifen for breast cancer: associated endometrial cancer. Cancer. 1990;65:1463–4.PubMedGoogle Scholar
  93. 93.
    Fornander T, Rutqvist LE, Cedermark B, Glas U, Mattsson A, Silfverswärd C, Skoog L, Somell A, Theve T, Wilking N. Adjuvant tamoxifen in early breast cancer: occurrence of new primary cancers. Lancet. 1989;1:117–20.PubMedGoogle Scholar
  94. 94.
    Seoud MA, Johnson J, Weed JC. Gynecologic tumors in tamoxifen-treated women with breast cancer. Obstet Gynecol. 1993;82:165–9.PubMedGoogle Scholar
  95. 95.
    Carcangiu ML. Uterine pathology in tamoxifen-treated patients with breast cancer. Anat Pathol. 1997;2:53–70.PubMedGoogle Scholar
  96. 96.
    Braithwaite RS, Chlebowski RT, Lau J, George S, Hess R, Col NF. Meta-analysis of vascular and neoplastic events associated with tamoxifen. J Gen Intern Med. 2003;18:937–47.PubMedPubMedCentralGoogle Scholar
  97. 97.
    Fisher B, Costantino JP, Redmond CK, Fisher ER, Wickerham DL, Cronin WM. Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14. J Natl Cancer Inst. 1994;86:527–37.PubMedGoogle Scholar
  98. 98.
    Davies C, Pan H, Godwin J, Gray R, Arriagada R, Raina V, et al. Adjuvant Tamoxifen: Longer Against Shorter (ATLAS) Collaborative Group: long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. Lancet. 2013;381:805–16.PubMedPubMedCentralGoogle Scholar
  99. 99.
    Dallenbach-Hellweg G, Schmidt D, Hellberg P, Bourne T, Kreuzwieser E, Dören M, Rydh W, Rudenstam G, Granberg S. The endometrium in breast cancer patients on tamoxifen. Arch Gynecol Obstet. 2000;263:170–7.PubMedGoogle Scholar
  100. 100.
    Deligdisch L, Kalir T, Cohen CJ, de Latour M, Le Bouedec G, Penault-Llorca F. Endometrial histopathology in 700 patients treated with tamoxifen for breast cancer. Gynecol Oncol. 2000;78:181–6.PubMedGoogle Scholar
  101. 101.
    Bland AE, Calingaert B, Secord AA, Lee PS, Valea FA, Berchuck A, Soper JT, Havrilesky L. Relationship between tamoxifen use and high risk endometrial cancer histologic types. Gynecol Oncol. 2009;112:150–4.PubMedGoogle Scholar
  102. 102.
    Cohen I, Azaria R, Fishman A, Tepper R, Shapira J, Beyth Y. Endometrial cancers in postmenopausal breast cancer patients with tamoxifen treatment. Int J Gynecol Pathol. 1999;18:304–9.PubMedGoogle Scholar
  103. 103.
    Barakat RR, Wong G, Curtin JP, Vlamis V, Hoskins WJ. Tamoxifen use in breast cancer patients who subsequently develop corpus cancer is not associated with a higher incidence of adverse histologic features. Gynecol Oncol. 1994;55:164–8.PubMedGoogle Scholar
  104. 104.
    Fisher B, Costantino JP, Wickerham DL, Redmond CK, Kavanah M, Cronin WM, Vogel V, Robidoux A, Dimitrov N, Atkins J, Daly M, Wieand S, Tan-Chiu E, Ford L, Wolmark N. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst. 1998;90:1371–88.PubMedGoogle Scholar
  105. 105.
    Wright JD, Desai VB, Chen L, Burke WM, Tergas AI, Hou JY, Accordino M, Ananth CV, Neugut AI, Hershman DL. Utilization of gynecologic services in women with breast cancer receiving hormonal therapy. Am J Obstet Gynecol. 2017;217:59.e1–12.PubMedPubMedCentralGoogle Scholar
  106. 106.
    Wickerham DL, Fisher B, Wolmark N, Bryant J, Costantino J, Bernstein L, Runowicz CD. Association of tamoxifen and uterine sarcoma. J Clin Oncol. 2002;20:2758–60.PubMedGoogle Scholar
  107. 107.
    Clement PB, Oliva E. Young RH: üü adenosarcoma of the uterine corpus associated with tamoxifen therapy: a report of six cases and a review of tamoxifen-associated endometrial lesions. Int J Gynecol Pathol. 1996;15:222–9.PubMedGoogle Scholar
  108. 108.
    McCluggage WG, Abdulkader M, Price JH, Kelehan P, Hamilton S, Beattie J, Al-Nafussi A. Uterine carcinosarcomas in patients receiving tamoxifen. A report of 19 cases. Int J Gynecol Cancer. 2000;10:280–4.PubMedGoogle Scholar
  109. 109.
    Swerdlow AJ, Jones ME. British Tamoxifen Second Cancer Study Group: Tamoxifen treatment for breast cancer and risk of endometrial cancer: a case-control study. J Natl Cancer Inst. 2005;97:375–84.PubMedGoogle Scholar
  110. 110.
    Matsuo K, Ross MS, Bush SH, Yunokawa M, Blake EA, Takano T, Ueda Y, Baba T, Satoh S, Shida M, Ikeda Y, Adachi S, Yokoyama T, Takekuma M, Takeuchi S, Nishimura M, Iwasaki K, Yanai S, Klobocista MM, Johnson MS, Machida H, Hasegawa K, Miyake TM, Nagano T, Pejovic T, Shahzad MM, Im DD, Omatsu K, Ueland FR, Kelley JL, Roman LD. Tumor characteristics and survival outcomes of women with tamoxifen-related uterine carcinosarcoma. Gynecol Oncol. 2017;144:329–35.PubMedGoogle Scholar
  111. 111.
    Nuovo MA, Nuovo GJ, McCaffrey RM, Levine RU, Barron B, Winkler B. Endometrial polyps in postmenopausal patients receiving tamoxifen. Int J Gynecol Pathol. 1989;8:125–31.PubMedGoogle Scholar
  112. 112.
    Corley D, Rowe J, Curtis MT, Hogan WM, Noumoff JS, Livolsi VA. Postmenopausal bleeding from unusual endometrial polyps in women on chronic tamoxifen therapy. Obstet Gynecol. 1992;79:111–6.PubMedGoogle Scholar
  113. 113.
    Lahti E, Blanco G, Kauppila A, Apaja-Sarkkinen M, Taskinen PJ, Laatikainen T. Endometrial changes in postmenopausal breast cancer patients receiving tamoxifen. Obstet Gynecol. 1993;81:660–4.PubMedGoogle Scholar
  114. 114.
    Kennedy MM, Baigrie CF, Manek S. Tamoxifen and the endometrium: review of 102 cases and comparison with HRT-related and non-HRT-related endometrial pathology. Int J Gynecol Pathol. 1999;18:130–7.PubMedGoogle Scholar
  115. 115.
    Cohen I, Azaria R, Bernheim J, Shapira J, Beyth Y. Risk factors of endometrial polyps resected from postmenopausal patients with breast carcinoma treated with tamoxifen. Cancer. 2001;92:1151–5.PubMedGoogle Scholar
  116. 116.
    Liedman R, Lindahl B, Andolf E, Willen R, Ingvar C, Ranstam J. Disaccordance between estimation of endometrial thickness as measured by transvaginal ultrasound compared with hysteroscopy and directed biopsy in breast cancer patients treated with tamoxifen. Anticancer Res. 2000;20:4889–91.PubMedGoogle Scholar
  117. 117.
    Sasaki LMP, Andrade KRC, Figueiredo ACMG, Wanderley MDS, Pereira MG. Factors associated with malignancy in hysteroscopically resected endometrial polyps: a systematic review and meta-analysis. J Minim Invasive Gynecol. 2018;25:1–9.Google Scholar
  118. 118.
    Schlesinger C, Kamoi S, Ascher SM, Kendell M, Lage JM, Silverberg SG. Endometrial polyps: a comparison study of patients receiving tamoxifen with two control groups. Int J Gynecol Pathol. 1998;17:302–11.PubMedGoogle Scholar
  119. 119.
    Biron-Shental T, Tepper R, Fishman A, Shapira J, Cohen I. Recurrent endometrial polyps in postmenopausal breast cancer patients on tamoxifen. Gynecol Oncol. 2003;90:382–6.PubMedGoogle Scholar
  120. 120.
    Di Benedetto L, Giovanale V, Caserta D. Endometrial tubal metaplasia in a young puerperal woman after breast cancer. Int J Clin Exp Pathol. 2015;8:7610–3.PubMedPubMedCentralGoogle Scholar
  121. 121.
    Cohen I, Bernheim J, Azaria R, Tepper R, Sharony R, Beyth Y. Malignant endometrial polyps in postmenopausal breast cancer tamoxifen-treated patients. Gynecol Oncol. 1999;75:136–41.PubMedGoogle Scholar
  122. 122.
    McCluggage WG, Sumathi VP, McManus DT. Uterine serous carcinoma and endometrial intraepithelial carcinoma arising in endometrial polyps: report of 5 cases, including 2 associated with tamoxifen therapy. Hum Pathol. 2003;34:939–43.PubMedGoogle Scholar
  123. 123.
    Dominick S, Hickey M, Chin J, Su HI. Levonorgestrel intrauterine system for endometrial protection in women with breast cancer on adjuvant tamoxifen. Cochrane Database Syst Rev. 2015;12:CD007245.Google Scholar
  124. 124.
    Cummings SR, Eckert S, Krueger KA, Grady D, Powles TJ, Cauley JA, Norton L, Nickelsen T, Bjarnason NH, Morrow M, Lippman ME, Black D, Glusman JE, Costa A, Jordan VC. The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation. JAMA. 1999;281:2189–97.PubMedGoogle Scholar
  125. 125.
    Goldstein SR. Update on raloxifene to prevent endometrial-breast cancer. Eur J Cancer. 2000;36(Suppl 4):S54–6.PubMedGoogle Scholar
  126. 126.
    Martino S, Disch D, Dowsett SA, Keech CA, Mershon JL. Safety assessment of raloxifene over eight years in a clinical trial setting. Curr Med Res Opin. 2005;21:1441–52.PubMedGoogle Scholar
  127. 127.
    Boss SM, Huster WJ, Neild JA, Glant MD, Eisenhut CC, Draper MW. Effects of raloxifene hydrochloride on the endometrium of postmenopausal women. Am J Obstet Gynecol. 1997;177:1458–64.PubMedGoogle Scholar
  128. 128.
    Davies GC, Huster WJ, Shen W, Mitlak B, Plouffe L, Shah A, Cohen FJ. Endometrial response to raloxifene compared with placebo, cyclical hormone replacement therapy, and unopposed estrogen in postmenopausal women. Menopause. 1999;6:188–95.PubMedGoogle Scholar
  129. 129.
    Delmas PD, Bjarnason NH, Mitlak BH, Ravoux AC, Shah AS, Huster WJ, Draper M, Christiansen C. Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. N Engl J Med. 1997;337:1641–7.PubMedGoogle Scholar
  130. 130.
    Goldstein SR, Scheele WH, Rajagopalan SK, Wilkie JL, Walsh BW, Parsons AK. A 12-month comparative study of raloxifene, estrogen, and placebo on the postmenopausal endometrium. Obstet Gynecol. 2000;95:95–103.PubMedGoogle Scholar
  131. 131.
    DeMichele A, Troxel AB, Berlin JA, Weber AL, Bunin GR, Turzo E, Schinnar R, Burgh D, Berlin M, Rubin SC, Rebbeck TR, Strom BL. Impact of raloxifene or tamoxifen use on endometrial cancer risk: a population-based case-control study. J Clin Oncol. 2008;26:4151–9.PubMedPubMedCentralGoogle Scholar
  132. 132.
    Benda JA. Clomiphene’s effect on endometrium in infertility. Int J Gynecol Pathol. 1992;11:273–82.PubMedGoogle Scholar
  133. 133.
    Birkenfeld A, Navot D, Levij IS, Laufer N, Beier-Hellwig K, Goecke C, Schenker JG, Beier HM. Advanced secretory changes in the proliferative human endometrial epithelium following clomiphene citrate treatment. Fertil Steril. 1986;45:462–8.PubMedGoogle Scholar
  134. 134.
    Thatcher SS, Donachie KM, Glasier A, Hillier SG, Baird DT. The effects of clomiphene citrate on the histology of human endometrium in regularly cycling women undergoing in vitro fertilization. Fertil Steril. 1988;49:296–301.PubMedGoogle Scholar
  135. 135.
    Li TC, Warren MA, Murphy C, Sargeant S, Cooke ID. A prospective, randomised, cross-over study comparing the effects of clomiphene citrate and cyclofenil on endometrial morphology in the luteal phase of normal, fertile women. Br J Obstet Gynaecol. 1992;99:1008–13.PubMedGoogle Scholar
  136. 136.
    Triwitayakorn A, Suwajanakorn S, Triratanachat S, Sampatanukul P, Pruksananonda K, Sereepapong W. Effects of initiation day of clomiphene citrate on the endometrium of women with regular menstrual cycles. Fertil Steril. 2002;78:102–7.PubMedGoogle Scholar
  137. 137.
    Floyd WS. Danazol: endocrine and endometrial effects. Int J Fertil. 1980;25:75–80.PubMedGoogle Scholar
  138. 138.
    Fedele L, Marchini M, Bianchi S, Baglioni A, Bocciolone L, Nava S. Endometrial patterns during danazol and buserelin therapy for endometriosis: comparative structural and ultrastructural study. Obstet Gynecol. 1990;76:79–84.PubMedGoogle Scholar
  139. 139.
    Beaumont H, Augood C, Duckitt K, Lethaby A. Danazol for heavy menstrual bleeding. Cochrane Database Syst Rev. 2007;3:CD001017.Google Scholar
  140. 140.
    Robins JC. Therapies for the treatment of abnormal uterine bleeding. Curr Womens Health Rep. 2001;1:196–201.PubMedGoogle Scholar
  141. 141.
    Tan YH, Lethaby A. Pre-operative endometrial thinning agents before endometrial destruction for heavy menstrual bleeding. Cochrane Database Syst Rev. 2013;11:CD001124.Google Scholar
  142. 142.
    Bradley LD, Gueye N-A. The medical management of abnormal uterine bleeding in reproductive-aged women. Am J Obstet Gynecol. 2016;214:31–44.PubMedGoogle Scholar
  143. 143.
    Soh E, Sato K. Clinical effects of danazol on endometrial hyperplasia in menopausal and postmenopausal women. Cancer. 1990;66:983–8.PubMedGoogle Scholar
  144. 144.
    Tamaoka Y, Orikasa H, Sumi Y, Sakakura K, Kamei K, Nagatani M, Ezawa S. Direct effect of danazol on endometrial hyperplasia in adenomyotic women: treatment with danazol containing intrauterine device. Hum Cell. 2000;13:127–33.PubMedGoogle Scholar
  145. 145.
    Wentz AC, Jones GS, Sapp KC, King TM. Progestational activity of danazol in the human female subject. Am J Obstet Gynecol. 1976;126:378–84.PubMedGoogle Scholar
  146. 146.
    Marchini M, Fedele L, Bianchi S, Di Nola G, Nava S, Vercellini P. Endometrial patterns during therapy with danazol or gestrinone for endometriosis: structural and ultrastructural study. Hum Pathol. 1992;23:51–6.PubMedGoogle Scholar
  147. 147.
    Jeppsson S, Mellquist P, Rannevik G. Short-term effects of danazol on endometrial histology. Acta Obstet Gynecol Scand Suppl. 1984;123:41–4.PubMedGoogle Scholar
  148. 148.
    Fedele L, Bianchi S, Marchini M, Di Nola G. Histological impact of medical therapy – clinical implications. Br J Obstet Gynaecol. 1995;102(Suppl 12):8–11.PubMedGoogle Scholar
  149. 149.
    Brooks PG, Serden SP, Davos I. Hormonal inhibition of the endometrium for resectoscopic endometrial ablation. Am J Obstet Gynecol. 1991;164:1601–6; discussion 1606–1608.PubMedGoogle Scholar
  150. 150.
    Reshef E, Segars JH, Hill GA, Pridham DD, Yussman MA, Wentz AC. Endometrial inadequacy after treatment with human menopausal gonadotropin/human chorionic gonadotropin. Fertil Steril. 1990;54:1012–6.PubMedGoogle Scholar
  151. 151.
    Bonhoff A, Naether O, Johannisson E, Bohnet HG. Morphometric characteristics of endometrial biopsies after different types of ovarian stimulation for infertility treatment. Fertil Steril. 1993;59:560–6.PubMedGoogle Scholar
  152. 152.
    Campbell BF, Phipps WR, Nagel TC, Tagatz GE. Endometrial biopsies during treatment with subcutaneous pulsatile gonadotropin-releasing hormone and luteal-phase human chorionic gonadotropin. Int J Fertil. 1988;33:329–33.PubMedGoogle Scholar
  153. 153.
    Sterzik K, Dallenbach C, Schneider V, Sasse V, Dallenbach-Hellweg G. In vitro fertilization: the degree of endometrial insufficiency varies with the type of ovarian stimulation. Fertil Steril. 1988;50:457–62.PubMedGoogle Scholar
  154. 154.
    Garcia JE, Acosta AA, Hsiu JG, Jones HW. Advanced endometrial maturation after ovulation induction with human menopausal gonadotropin/human chorionic gonadotropin for in vitro fertilization. Fertil Steril. 1984;41:31–5.PubMedGoogle Scholar
  155. 155.
    Sharma V, Whitehead M, Mason B, Pryse-Davies J, Ryder T, Dowsett M, Campbell S, Collins W. Influence of superovulation on endometrial and embryonic development. Fertil Steril. 1990;53:822–9.PubMedGoogle Scholar
  156. 156.
    Child TJ, Gulekli B, Sylvestre C, Tan SL. Ultrasonographic assessment of endometrial receptivity at embryo transfer in an in vitro maturation of oocyte program. Fertil Steril. 2003;79:656–8.PubMedGoogle Scholar
  157. 157.
    Elizur SE, Son W-Y, Yap R, Gidoni Y, Levin D, Demirtas E, Tan S-L. Comparison of low-dose human menopausal gonadotropin and micronized 17beta-estradiol supplementation in in vitro maturation cycles with thin endometrial lining. Fertil Steril. 2009;92:907–12.PubMedGoogle Scholar
  158. 158.
    Casper RF. Clinical uses of gonadotropin-releasing hormone analogues. CMAJ. 1991;144:153–8.PubMedPubMedCentralGoogle Scholar
  159. 159.
    Lethaby A, Puscasiu L, Vollenhoven B. Preoperative medical therapy before surgery for uterine fibroids. Cochrane Database Syst Rev. 2017;11:CD000547.PubMedGoogle Scholar
  160. 160.
    Lemay A, Jean C, Faure N. Endometrial histology during intermittent intranasal luteinizing hormone-releasing hormone (LH-RH) agonist sequentially combined with an oral progestogen as an antiovulatory contraceptive approach. Fertil Steril. 1987;48:775–82.PubMedGoogle Scholar
  161. 161.
    Spitz IM, Bardin CW. Mifepristone (RU 486)—a modulator of progestin and glucocorticoid action. N Engl J Med. 1993;329:404–12.PubMedGoogle Scholar
  162. 162.
    Johannisson E, Oberholzer M, Swahn ML, Bygdeman M. Vascular changes in the human endometrium following the administration of the progesterone antagonist RU 486. Contraception. 1989;39:103–17.PubMedGoogle Scholar
  163. 163.
    Swahn ML, Bygdeman M. The effect of the antiprogestin RU 486 on uterine contractility and sensitivity to prostaglandin and oxytocin. Br J Obstet Gynaecol. 1988;95:126–34.PubMedGoogle Scholar
  164. 164.
    Spitz IM. Mifepristone: where do we come from and where are we going? Clinical development over a quarter of a century. Contraception. 2010;82:442–52.PubMedGoogle Scholar
  165. 165.
    Croxatto HB, Kovács L, Massai R, Resch BA, Fuentealba B, Salvatierra AM, Croxatto HD, Zalányi S, Viski S, Krenács L. Effects of long-term low-dose mifepristone on reproductive function in women. Hum Reprod. 1998;13:793–8.PubMedGoogle Scholar
  166. 166.
    Croxatto HB, Salvatierra AM, Croxatto HD, Fuentealba B. Effects of continuous treatment with low dose mifepristone throughout one menstrual cycle. Hum Reprod. 1993;8:201–7.PubMedGoogle Scholar
  167. 167.
    Swahn ML, Bygdeman M, Cekan S, Xing S, Masironi B, Johannisson E. The effect of RU 486 administered during the early luteal phase on bleeding pattern, hormonal parameters and endometrium. Hum Reprod. 1990;5:402–8.PubMedGoogle Scholar
  168. 168.
    Li TC, Dockery P, Thomas P, Rogers AW, Lenton EA, Cooke ID. The effects of progesterone receptor blockade in the luteal phase of normal fertile women. Fertil Steril. 1988;50:732–42.PubMedGoogle Scholar
  169. 169.
    Batista MC, Cartledge TP, Zellmer AW, Merino MJ, Axiotis C, Loriaux DL, Nieman LK. Delayed endometrial maturation induced by daily administration of the antiprogestin RU 486: a potential new contraceptive strategy. Am J Obstet Gynecol. 1992;167:60–5.PubMedGoogle Scholar
  170. 170.
    Cameron ST, Critchley HO, Thong KJ, Buckley CH, Williams AR, Baird DT. Effects of daily low dose mifepristone on endometrial maturation and proliferation. Hum Reprod. 1996;11:2518–26.PubMedGoogle Scholar
  171. 171.
    Heikinheimo O, Hsiu JG, Gordon K, Kim S, Williams RF, Gibbons WE, Hodgen GD. Endometrial effects of RU486 in primates – antiproliferative action despite signs of estrogen action and increased cyclin-B expression. J Steroid Biochem Mol Biol. 1996;59:179–90.PubMedGoogle Scholar
  172. 172.
    Gemzell-Danielsson K, Westlund P, Johannisson E, Swahn ML, Bygdeman M, Seppälä M. Effect of low weekly doses of mifepristone on ovarian function and endometrial development. Hum Reprod. 1996;11:256–64.PubMedGoogle Scholar
  173. 173.
    Jimenez-Moreno V, Billeter M, Liu CQ, Gordon K, Mahony M. Local effects of mifepristone on the nonhuman primate endometrium. Fertil Steril. 2000;74:134–40.PubMedGoogle Scholar
  174. 174.
    Baird DT, Brown A, Critchley HOD, Williams AR, Lin S, Cheng L. Effect of long-term treatment with low-dose mifepristone on the endometrium. Hum Reprod. 2003;18:61–8.PubMedGoogle Scholar
  175. 175.
    Newfield RS, Spitz IM, Isacson C, New MI. Long-term mifepristone (RU486) therapy resulting in massive benign endometrial hyperplasia. Clin Endocrinol. 2001;54:399–404.Google Scholar
  176. 176.
    Eisinger SH, Meldrum S, Fiscella K, le Roux HD, Guzick DS. Low-dose mifepristone for uterine leiomyomata. Obstet Gynecol. 2003;101:243–50.PubMedGoogle Scholar
  177. 177.
    Horne FM, Blithe DL. Progesterone receptor modulators and the endometrium: changes and consequences. Hum Reprod Update. 2007;13:567–80.PubMedGoogle Scholar
  178. 178.
    Koering MJ, Healy DL, Hodgen GD. Morphologic response of endometrium to a progesterone receptor antagonist, RU486, in monkeys. Fertil Steril. 1986;45:280–7.PubMedGoogle Scholar
  179. 179.
    Wheeler DT, Bristow RE, Kurman RJ. Histologic alterations in endometrial hyperplasia and well-differentiated carcinoma treated with progestins. Am J Surg Pathol. 2007;31:988–98.PubMedGoogle Scholar
  180. 180.
    Parra-Herran C, Cesari M, Djordjevic B, Grondin K, Kinloch M, Köbel M, Pirzada A, Plotkin A, Gilks CB. Canadian consensus-based and evidence-based guidelines for benign endometrial pathology reporting in biopsy material. Int J Gynecol Pathol. 2018 Apr 19. doi:10.1097/PGP.0000000000000481. [Epub ahead of print].Google Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  • Tricia A. Murdock
    • 1
  • Emanuela F. T. Veras
    • 1
  • Robert J. Kurman
    • 1
  • Michael T. Mazur
    • 2
  1. 1.Department of PathologyThe Johns Hopkins HospitalBaltimoreUSA
  2. 2.Department of Pathology and Laboratory MedicineState University of New York Upstate Medical UniversitySyracuseUSA

Personalised recommendations